Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BDSX Biodesix	$0.43 -4.3%	$0.36	$0.17 ▼ $2.04	$62.91M	0.99	3.84 million shs	5.17 million shs
BNR Burning Rock Biotech	$8.55 +3.2%	$5.87	$2.18 ▼ $11.12	$91.85M	0.83	31,085 shs	30,430 shs
CCM Concord Medical Services	$5.23 -4.1%	$5.47	$3.80 ▼ $10.77	$22.68M	-0.94	20,721 shs	610 shs
EUDA EUDA Health	$2.10 -5.2%	$3.04	$2.05 ▼ $6.30	$77.85M	-0.06	96,400 shs	157,070 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BDSX Biodesix	-5.02%	+5.33%	+15.02%	+46.46%	-75.87%
BNR Burning Rock Biotech	-2.70%	-16.26%	+42.69%	+167.42%	+44.68%
CCM Concord Medical Services	-2.28%	-1.20%	+2.49%	-22.91%	-16.54%
EUDA EUDA Health	-3.49%	-9.05%	-32.62%	-36.86%	-55.26%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BDSX Biodesix	3.5722 of 5 stars	3.4	5.0	3.3	2.5	0.6
BNR Burning Rock Biotech	0.8919 of 5 stars	0.0	3.0	3.7	1.7	0.0
CCM Concord Medical Services	0.4784 of 5 stars	0.0	3.0	0.8	1.7	0.6
EUDA EUDA Health	1.0406 of 5 stars	0.0	5.0	2.6	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BDSX Biodesix	2.80	Moderate Buy	$1.75	309.84% Upside
BNR Burning Rock Biotech	0.00	N/A	N/A	N/A
CCM Concord Medical Services	0.00	N/A	N/A	N/A
EUDA EUDA Health	4.00	Strong Buy	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BDSX Biodesix	$76.56M	0.82	N/A	N/A	$0.01 per share	42.70
BNR Burning Rock Biotech	$523.28M	0.18	N/A	N/A	$7.39 per share	1.16
CCM Concord Medical Services	$52.60M	0.43	N/A	N/A	$51.05 per share	0.10
EUDA EUDA Health	$4.01M	19.41	N/A	N/A	($0.07) per share	-29.93

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BDSX Biodesix	-$42.93M	-$0.29	N/A	N/A	N/A	-53.66%	-269.67%	-43.94%	11/7/2025 (Estimated)
BNR Burning Rock Biotech	-$47.49M	-$1.89	N/A	∞	N/A	-45.41%	-38.33%	-25.34%	N/A
CCM Concord Medical Services	-$42.23M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
EUDA EUDA Health	-$15.36M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Latest CCM, BNR, EUDA, and BDSX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/7/2025	Q2 2025	BDSX Biodesix	-$0.07	-$0.08	-$0.01	-$0.08	$18.47 million	$20.02 million
6/6/2025	Q1 2025	BNR Burning Rock Biotech	N/A	-$0.17	N/A	-$0.17	N/A	$18.34 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BDSX Biodesix	N/A	N/A	N/A	N/A	N/A
BNR Burning Rock Biotech	N/A	N/A	N/A	N/A	N/A
CCM Concord Medical Services	N/A	N/A	N/A	N/A	N/A
EUDA EUDA Health	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BDSX Biodesix	41.11	2.14	2.14
BNR Burning Rock Biotech	N/A	3.02	2.76
CCM Concord Medical Services	1.67	0.46	0.45
EUDA EUDA Health	N/A	0.18	0.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BDSX Biodesix	20.96%
BNR Burning Rock Biotech	30.03%
CCM Concord Medical Services	N/A
EUDA EUDA Health	4.35%

Insider Ownership

Company	Insider Ownership
BDSX Biodesix	30.10%
BNR Burning Rock Biotech	30.30%
CCM Concord Medical Services	46.50%
EUDA EUDA Health	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BDSX Biodesix	220	146.63 million	102.50 million	Optionable
BNR Burning Rock Biotech	1,390	10.76 million	7.50 million	Not Optionable
CCM Concord Medical Services	970	4.34 million	2.32 million	Not Optionable
EUDA EUDA Health	2	37.16 million	N/A	Not Optionable

CCM, BNR, EUDA, and BDSX Headlines

Recent News About These Companies

EUDA Signs Letter of Intent to Potentially Acquire Chemokine Pte Ltd

August 28 at 8:46 PM | finance.yahoo.com

Highly potent cannabis products tied to risk of psychosis, schizophrenia, and addiction, study finds

August 27 at 5:45 AM | msn.com

EUDA Expands Wellness Product Portfolio With A Next-Generation Immune Health Supplement

August 26 at 12:40 AM | markets.businessinsider.com

EUDA Health Secures Global Rights for New Immune Supplement

August 26 at 5:30 PM | tipranks.com

EUDA Health (NASDAQ:EUDA) Stock Price Up 2.8% - Time to Buy?

August 14, 2025 | marketbeat.com

EUDA Health Holdings Secures $10 Million Convertible Note Agreement

August 13, 2025 | theglobeandmail.com

New toolkit supports hepatitis prevention and care in European prisons

August 7, 2025 | msn.com

EUDA Health Holdings Limited (NASDAQ:EUDA) stock most popular amongst retail investors who own 47%, while private companies hold 26%

July 30, 2025 | finance.yahoo.com

BRIEF-Euda Health Holdings Files For Offering Of Up To $10 Million Of Ordinary Shares

June 25, 2025 | sg.finance.yahoo.com

EUDA Health Holdings Initiates $10 Million At The Market Offering

June 24, 2025 | tipranks.com

EUDA Health’s 47% decline validates InvestingPro’s overvalued warning

June 10, 2025 | investing.com

Midwest Addiction Counsellor Warns “No Illicit Drug Is Absolutely Safe”

June 9, 2025 | clare.fmC

Rising deaths, fake pills, gang violence: How the EU is struggling to cope with illegal drug problem

June 6, 2025 | msn.com

Report: Synthetic Opioids, Cathinones Surge in Europe

June 5, 2025 | occrp.orgO

Poland is becoming Europe’s factory for ‘bath salts’ drugs, EU agency warns

June 5, 2025 | politico.euP

Health risks of synthetic drug use in Europe still unknown

June 5, 2025 | msn.com

EU drug report warns of rising cocaine use and synthetic drug threats across Europe

June 5, 2025 | irishexaminer.comI

Synthetic drugs pose unprecedented health risk to Europe

June 5, 2025 | lemonde.frL

EUDA Health Holdings Full Year 2024 Earnings: US$0.54 loss per share (vs US$0.37 loss in FY 2023)

May 2, 2025 | finance.yahoo.com

EUDA Partners with Authorized Distributor of Guangdong Cell Biotech to Offer Stem Cell Therapies to Customers in Singapore and Malaysia

April 24, 2025 | finance.yahoo.com

Something in the water: Pee from 130 European cities reveals hike in recreational drug use

March 24, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CCM, BNR, EUDA, and BDSX Company Descriptions

Biodesix NASDAQ:BDSX

$0.43 -0.02 (-4.35%)

As of 03:50 PM Eastern

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

Burning Rock Biotech NASDAQ:BNR

$8.55 +0.26 (+3.18%)

As of 03:50 PM Eastern

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.

Concord Medical Services NYSE:CCM

$5.23 -0.22 (-4.11%)

As of 01:30 PM Eastern

Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. It operates in two segments, Network and Hospital. The company's services include linear accelerators and external beam radiotherapy, proton therapy system, gamma knife radiosurgery, and diagnostic imaging services. Its other treatments and diagnostic services comprise positron emission tomography-computed tomography and magnetic resonance imaging scanners. In addition, the company provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, as well as helps to recruit and determine the compensation of doctors and other medical personnel. Further, it offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, the company operates specialty cancer hospitals, which offers radiation, imaging, test laboratory, inpatient, and nursing services. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, the People's Republic of China.

EUDA Health NASDAQ:EUDA

$2.10 -0.12 (-5.20%)

As of 03:50 PM Eastern

EUDA Health Holdings Limited operates as a healthcare specialty company. The company operates through two segments, Medical Services and Property Management Services. It offers a range of specialty care services to patients; and operates medical facility general practice clinic that provides holistic care for various illnesses. The company is also involved in the property management that services shopping malls, business office building, or residential apartments. EUDA Health Holdings Limited is headquartered in Singapore.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time